The Institute for Clinical and Economic Review says new CGRP inhibitor treatments for chronic and episodic migraine probably won’t be cost effective. But the analysis omits five important components.

**What’s Missing from ICER’s Analysis of Migraine Therapies?**

- **Valuable Data:** ICER chose to issue its report before long-term or real-world data were available.

- **Potential Impact on Mortality:** ICER ignores research that demonstrates migraine patients’ elevated risk of dying from heart problems and strokes.

- **Effect on the Opioid Crisis:** ICER excludes the value that preventive migraine treatment could have on reducing opioid dependence and addiction.

- **Full Disclosure:** ICER withholds the data it used to calculate CGRP inhibitors’ effectiveness.

- **Depression Comorbidity:** ICER does not account for treatment’s potential impact on depression, which affects nearly 80 percent of migraine patients and is a risk factor for suicide.